Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$35.48 USD
-0.46 (-1.28%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $35.49 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Collegium Pharmaceutical (COLL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$40.00 | $41.00 | $39.00 | 11.30% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Collegium Pharmaceutical comes to $40.00. The forecasts range from a low of $39.00 to a high of $41.00. The average price target represents an increase of 11.3% from the last closing price of $35.94.
Analyst Price Targets (4 )
Broker Rating
Collegium Pharmaceutical currently has an average brokerage recommendation (ABR) of 1.83 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.83 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, three are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 16.67% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.83 | 1.83 | 1.83 | 1.83 | 1.83 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/11/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
2/23/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
2/23/2024 | H.C. Wainwright & Co. | Oren Livnat | Hold | Hold |
1/4/2024 | Truist Securities | Leszek Sulewski | Strong Buy | Strong Buy |
11/8/2023 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.83 |
ABR (Last week) | 1.83 |
# of Recs in ABR | 6 |
Average Target Price | $40.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 147 of 252 |
Current Quarter EPS Est: | 1.50 |